Esuberaprost (GP-1681), a drug intended for participants with pulmonary arterial hypertension, was under investigation in clinical trial NCT03657095 to evaluate its efficacy and safety. It is grouped under the following drug class(es): Prostaglandins. The directory classifies it as a under development API with a synthetic source/manufacturing origin. Other names for this substance include Beraprost, (+)-, BPS-314d DRUG SUBSTANCE, (8S, 9S and 16S)Beraprost Isomer. Its PubChem CID is 10501053.
Esuberaprost
| CAS No | 94132-88-4 |
|---|---|
| Molecular Formula | C24H30O5 |
| Molecular Weight | 398.5 g/mol |
| Synonyms | 4-[(1R,2R,3aS,8bS)-2-hydroxy-1-[(E,3S,4S)-3-hydroxy-4-methyloct-1-en-6-ynyl]-2,3,3a,8b-tetrahydro-1H-cyclopenta[b][1]benzofuran-5-yl]butanoic acid |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Esuberaprost (GP-1681), a drug intended for participants with pulmonary arterial hypertension, was under investigation in clinical trial NCT03657095 to evaluate its efficacy and safety.
The listed CAS number is 94132-88-4.
The listed molecular formula is C24H30O5.
The listed molecular weight is 398.5 g/mol.
4-[(1R,2R,3aS,8bS)-2-hydroxy-1-[(E,3S,4S)-3-hydroxy-4-methyloct-1-en-6-ynyl]-2,3,3a,8b-tetrahydro-1H-cyclopenta[b][1]benzofuran-5-yl]butanoic acid.
The source lists Beraprost, (+)-, BPS-314d DRUG SUBSTANCE, (8S, 9S and 16S)Beraprost Isomer.